KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Non Operating Income (2016 - 2025)

AbbVie (ABBV) has disclosed Non Operating Income for 14 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 706.67% to -$1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.8 billion, a 78.8% decrease, with the full-year FY2025 number at -$5.8 billion, down 78.8% from a year prior.
  • Non Operating Income was -$1.2 billion for Q4 2025 at AbbVie, down from -$503.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $776.0 million in Q1 2022 to a low of -$2.7 billion in Q2 2021.
  • A 5-year average of -$932.9 million and a median of -$1.2 billion in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 1671.43% in 2022, then plummeted 1320.0% in 2024.
  • AbbVie's Non Operating Income stood at -$216.0 million in 2021, then crashed by 835.65% to -$2.0 billion in 2022, then rose by 23.01% to -$1.6 billion in 2023, then skyrocketed by 90.36% to -$150.0 million in 2024, then tumbled by 706.67% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Non Operating Income are -$1.2 billion (Q4 2025), -$503.0 million (Q3 2025), and -$2.6 billion (Q2 2025).